PI-RADS V2 ve V2.1'in Tanısal Performansının ve Her İki Sürümdeki Gözlemciler Arası Uyumun Karşılaştırılması

Yıl 2024, Cilt: 34 Sayı: 2, 223 - 229, 30.04.2024

Ahmet Baytok , Mustafa Koplay , Halil Özer , Ömer Faruk Topaloğlu , Mehmet Kaynar , Serdar Göktaş , Ali Furkan Batur

https://doi.org/10.54005/geneltip.1378687

Öz

Amaç: PI-RADS v2 ile v2.1 'nin klinik olarak anlamlı prostat kanserlerinin saptanmasına yönelik tanısal performansı ve gözlemciler arası uyumunu karşılaştırmak.
Gereç ve Yöntem: Bu retrospektif çalışmaya dahil edilen 258 hasta ve 394 nodülün mpMRI görüntüleri 3T MR'da elde edilmiş ve iki radyolog tarafından PI-RADS v2 ve v2.1'e göre değerlendirildi. V2 ve v2.1 arasındaki duyarlılık ve özgüllük karşılaştırıldı. V2'den v2.1'in kullanımında yükseltilmiş ve indirgenmiş lezyonlarda klinik olarak anlamlı prostat kanserlerinin tespit oranları değerlendirildi. Gözlemciler arası uyum κ istatistikleri kullanılarak değerlendirildi.
Bulgular: PI-RADS v2.1 ve v2, csPCA tespitinde kategori ≥4 lezyonlar için periferik zonda yüksek duyarlılık ve düşük özgüllük (%100, %52,38) ve transizyonel zonda yüksek duyarlılık ve özgüllük (%92,86, %98,79) gösterdi, iki versiyon arasında anlamlı bir fark bulunamadı. Her iki sınıflandırmaya göre de gözlemciler arası uyum istatistiksel olarak anlamlı ve transizyonel zonda çok zayıf (sırasıyla κ=0,383, κ=0,279), periferik zonda çok güçlü (κ=0,869) ve benzerdi.
Sonuç: PI-RADS v2 ve v2.1'in tanısal performansı, klinik olarak anlamlı kanserlerin ve her iki bölgedeki tüm kanserlerin tespitinde benzer bulundu. Geçiş bölgesindeki kategori 2+1 lezyonlarda klinik olarak anlamlı kanser tespit oranı, kategori 2 lezyonlara göre daha yüksekti ancak istatistiksel olarak anlamlı değildi. Her iki versiyonda da gözlemciler arası uyum transizyonel zonda düşük, periferik zonda ise çok güçlüydü.

Anahtar Kelimeler

PI-RADS V2.1, klinik olarak anlamlı prostat kanseri, gözlemciler arası uyum

Comparison of Diagnostic Performance of PI-RADS V2 and V2.1 and Interobserver Agreement in Both Versions

Öz

Objective: To compare the diagnostic performance for the detection of clinically significant prostate cancers and interobserver agreement between PI-RADS v2 and v2.1
Material and Method: The mpMRI images of 258 patients and 394 nodüles included in this retrospective study were obtained on 3T MR and evaluated by two radiologists according to PI-RADS v2 and v2.1. Sensitivity and specificity between v2 and v2.1 compared. Detection rates for clinically significant prostate cancers of upgraded and downgraded lesions in the use of v2.1 from v2 were assessed. Interobserver agreement was assessed using κ statistics.
Results: PI-RADS v2.1 and v2 showed higher sensitivity and lower specificity (100%, 52.38%) in peripheral zone and showed higher sensitivity and specificity (92.86%, 98.79%) in transition zone for category ≥4 lesions in the detection of csPCa, not significantly difference was found between the two versions. Interobserver agreement was statistically significant and very weak in the transition zone (κ=0.383, κ=0.279, respectively), very strong in the peripheral zone (κ=0.869) according to both classifications and they were similar.
Conclusion: The diagnostic performance of PI-RADS v2 and v2.1 were found similar in detecting clinically significant cancers and all cancers in both zones. The clinically significant cancer detection rate in category 2+1 lesions in the transition zone was higher than in category 2 lesions but it wasn’t statistically significant. Interobserver agreement was low in the transition zone and very strong in the peripheral zone in both versions.

Anahtar Kelimeler

PI-RADS V2.1, clinically significant prostate cancer, interobserver agreement

Etik Beyan

Our institutional review board approved this retrospective study with a waiver of informed consent.

Kaynakça

• Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14. PMID: 24666839.
• Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18. PMID: 29552975.
• Prostate Imaging and Reporting and Data System: Version 2, PI-RADS Steering Committee, 2014
• Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012 Apr;22(4):746-57. doi: 10.1007/s00330-011-2377-y. Epub 2012 Feb 10. PMID: 22322308; PMCID: PMC3297750.
• Smith CP, Türkbey B. PI-RADS v2: Current standing and future outlook. Turk J Urol. 2018 May;44(3):189-194. doi: 10.5152/tud.2018.12144. Epub 2018 May 1. PMID: 29733790; PMCID: PMC5937636.
• Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1. PMID: 26427566; PMCID: PMC6467207.
• Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol. 2016 Jan;69(1):41-9. doi: 10.1016/j.eururo.2015.08.038. Epub 2015 Sep 8. PMID: 26361169; PMCID: PMC6364687.
• Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. PMID: 30898406.
• Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013 Jan;266(1):207-17. doi: 10.1148/radiol.12120281. Epub 2012 Nov 9. PMID: 23143029.
• Linhares Moreira AS, De Visschere P, Van Praet C, Villeirs G. How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1. Acta Radiol. 2021 Jun;62(6):839-847. doi: 10.1177/0284185120941831. Epub 2020 Jul 23. PMID: 32702998.
• Wei CG, Zhang YY, Pan P, Chen T, Yu HC et al. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. AJR Am J Roentgenol. 2021 May;216(5):1247-1256. doi: 10.2214/AJR.20.23883. Epub 2021 Feb 24. PMID: 32755220.
• Byun J, Park KJ, Kim MH, Kim JK. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience. J Magn Reson Imaging. 2020 Aug;52(2):577-586. doi: 10.1002/jmri.27080. Epub 2020 Feb 11. PMID: 32045072.
• Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol. 2017 Aug;72(2):177-188. doi: 10.1016/j.eururo.2017.01.042. Epub 2017 Feb 11. PMID: 28196723.
• Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019 Sep;76(3):284-303. doi: 10.1016/j.eururo.2019.04.043. Epub 2019 May 24. PMID: 31130434.
• Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N et al. Risk Stratification Among Men With Prostate Imaging Reporting and Data System Version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? AJR Am J Roentgenol. 2017 Dec;209(6):1272-1277. doi: 10.2214/AJR.17.18008. Epub 2017 Aug 31. PMID: 28858541; PMCID: PMC5732583.
• Thai JN, Narayanan HA, George AK, Siddiqui MM, Shah P et al. Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. Radiology. 2018 Aug;288(2):485-491. doi: 10.1148/radiol.2018170425. Epub 2018 May 22. PMID: 29786491; PMCID: PMC6071681.
• Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L et al. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology. 2017 Dec;285(3):859-869. doi: 10.1148/radiol.2017161316. Epub 2017 Jul 19. PMID: 28727501; PMCID: PMC5708285.
• Greer MD, Shih JH, Lay N, Barrett T, Bittencourt L et al. Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. AJR Am J Roentgenol. 2019 Mar 27:1-8. doi: 10.2214/AJR.18.20536. Epub ahead of print. PMID: 30917023; PMCID: PMC8268760.
• Rosenkrantz AB, Ginocchio LA, Cornfeld D, Froemming AT, Gupta RT et al. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology. 2016 Sep;280(3):793-804. doi: 10.1148/radiol.2016152542. Epub 2016 Apr 1. PMID: 27035179; PMCID: PMC5006735.
• Benndorf M, Hahn F, Krönig M, Jilg CA, Krauss T et al. Diagnostic performance and reproducibility of T2w based and diffusion-weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI. Eur J Radiol. 2017 Aug; 93:9-15. doi: 10.1016/j.ejrad.2017.05.015. Epub 2017 May 18. PMID: 28668436.
• Feng ZY, Wang L, Min XD, Wang SG, Wang GP, Cai J. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2. Chin Med J (Engl). 2016 Oct 20;129(20):2451-2459. doi: 10.4103/0366-6999.191771. PMID: 27748338; PMCID: PMC5072258.
• Tewes S, Mokov N, Hartung D, Schick V, Peters I et al. Standardized Reporting of Prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and Version 2. PLoS One. 2016 Sep 22;11(9): e0162879. doi: 10.1371/journal.pone.0162879. PMID: 27657729; PMCID: PMC5033350.
• Wang X, Bao J, Ping X, Hu C, Hou J et al. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer. Oncol Lett. 2018 Sep;16(3):3201-3206. doi: 10.3892/ol.2018.9038. Epub 2018 Jun 28. PMID: 30127915; PMCID: PMC6096261.
• Rosenkrantz AB, Kim S, Campbell N, Gaing B, Deng FM et al. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. AJR Am J Roentgenol. 2015 Mar;204(3): W266-72. doi: 10.2214/AJR.14.12955. PMID: 25714311.
• Bhayana R, O'Shea A, Anderson MA, Bradley WR, Gottumukkala RV et al. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists. AJR Am J Roentgenol. 2021 Jul;217(1):141-151. doi: 10.2214/AJR.20.24199. Epub 2020 Sep 9. PMID: 32903060.
• Hötker AM, Blüthgen C, Rupp NJ, Schneider AF, Eberli D et al. Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement. PLoS One. 2020 Oct 5;15(10):e0239975. doi: 10.1371/journal.pone.0239975. PMID: 33017413; PMCID: PMC7535021.